Aspen Pharmacare has secured a deal with Johnson & Johnson to make and sell a COVID-19 vaccine under its own brand.
On Tuesday, Aspen SA said the new deal would form the basis for negotiations of a definitive agreement on the manufacturing and sale of an Aspen-branded vaccine throughout Africa.
The new vaccine will be called Aspenovax.
It said this was subject to the signing of the definitive agreement lasting until 31 December 2026.
As part of the deal, J&J will grant Aspen a licence to its intellectual property.
It will also supply the substance for the jabs.
Through a previous agreement with Johnson & Johnson, Aspen has been filling and finishing over a hundred-million doses for distribution in Africa.
This is good news for Africa, which has seen a slower rollout compared to western countries.
More Stories
There’s Been An Improvement in Implementation Of Energy Action Plan – Ramokgopa
Waste To Energy: The Solution That Begs To Be Implemented
Stage 4 And 5 Blackouts Until Further Notice
Ramaphosa Appoints Panel To Probe Docking Of ‘Lady R’
Economists Predict Moderate Interest Rate Hike After Consumer Inflation Drop
Interest Rate Hikes And Home Insurance: How To Navigate The Changes
Karpowership Energy Deal Shouldn’t Be More Than Five Years – Ramokgopa
Sign Language Moves A Step Closer To Being SA’s 12th Official Language
Numsa To Meet Eskom For Third Round Of Wage Talks
Changemaker Honoured For Africa Education Nomination
Ramaphosa Confident There’ll Be Less Load Shedding ‘Within The Next Few Months’
G7 Agrees On Ukraine Jets, China ‘Economic Coercion’ Statement